    Elliot Ehrich | Alkermes , Inc. | ZoomInfo.com

	
        Compensation Information for Elliot W. Ehrich , Executive Vice President, Research and Development and Chief Medical Officer of ALKERMES PLC | Salary.com
    


























Enterprise
Small Business
Personal




Contact Us
Log In


































Salaries
Jobs
Education
Advice
























 





Elliot W. Ehrich 
Executive Compensation
As Executive Vice President, Research and Development and Chief Medical Officer at ALKERMES PLC, Elliot W. Ehrich  made $3,452,206 in total compensation.  Of this total $533,704 was received as a salary, $556,499 was received as a bonus, $1,606,518 was received in stock options, $742,210 was awarded as stock and $13,275 came from other types of compensation. This information is according to proxy statements filed for the 2016 fiscal year. 


ENTER AN EXECUTIVE OR COMPANY NAME
New Search


Go



The chart on this page features a breakdown of the total annual pay for Elliot W. Ehrich ,  Executive Vice President, Research and Development and Chief Medical Officer at ALKERMES PLC as reported in their proxy statements. 
Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ALKERMES PLC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ALKERMES PLC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.
Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.



Other Executives at this Company


James M. Frates 
Richard F. Pops 
Kathryn L. Biberstein 
Shane M. Cooke 







Elliot W. Ehrich 


Base Pay$533,704
Bonus + Incentive Comp$556,499
Total Cash Compensation$1,090,203


Stock Award Value$742,210
Option Award Value$1,606,518
Total Equity$2,348,728



Total Other$13,275



Total Compensation$3,452,206




Browse Executives by First Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z


Browse Companies by Company Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#



This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement. 
Use of Data / Disclaimer
The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.
What is a proxy statement?
A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.
The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.







    





 

 






     

privacy policy
terms of use
about us
contact us

©  Salary.com. All rights reserved.


US Salaries
Canadian Salaries
Purchase a Salary Report
Salaries by Category
Salaries by Income
Salaries by Industry
Popular Salaries
Negotiation Tips
Benefits Calculator
Search Job Openings
Job Openings by State
Job Openings by Category
Education by Career
Education by Level
Education by Major
Cost of Living Calculator
























 


Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















Elliot  Ehrich - Woodmere, NY | Intelius



























Sign In



We found Elliot  Ehrich in Woodmere, NY


Elliot  Ehrich

                                                                           Intelius found that Elliot  Ehrich  is  a male between 40 and 40 years old from Woodmere, NY.  We have connected them to
                5 addresses,
                1 phone,
                and 1 relative or associate.
         






Get Report Now

Age

Elliot  Ehrich is in his 40s

Elliot Has Lived In

Woodmere, NY
College Point, NY
Far Rockaway, NY

Elliot's Relatives

Suri Ehrich







Elliot  Ehrich



Zodiac SignScorpio



GenderMale



Professional Status
Chief Information Officer at Eliza Coffee Memorial Hospital



Get Report Now










Want to know more about Elliot? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Elliot, or use our people search engine to find others.
Get Background Check on Elliot  Ehrich
Get a Criminal Check on Elliot  Ehrich
Get a Public Record Report on Elliot  Ehrich
Get a People Search Report on Elliot  Ehrich


Elliot  Ehrich's Contact Information
Known Cities Lived In
Find out where Elliot  Ehrich has lived as well as Elliot  Ehrich's phone numbers and email addresses.




Elliot  Ehrich Has Lived in 2 States
New York Address for Elliot  Ehrich


140 N W*** L* 

Woodmere, NY


Has Lived In

Woodmere, NY
College Point, NY


Get Full Address Report










Phone Numbers Associated with Elliot  Ehrich

(256) ***-**** - Florence, AL 


Get Full Phone Report



Email Addresses Associated with Elliot  Ehrich

e**********h@***.com
e*****h@***.com
e**********y@***.net


Get Email Report




Elliot  Ehrich's Professional Information
Information regarding Elliot  Ehrich's professional history.  Find out previous places Elliot  Ehrich has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Elliot  Ehrich Has Worked at 1 Place
Company: Eliza Coffee Memorial Hospital
               Title: Chief Information Officer
Elliot  Ehrich's Experience
Title: Chief Information Officer
               Company: Eliza Coffee Memorial Hospital
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25
Additional Professional Information on Elliot  Ehrich

 See Elliot  Ehrich's LinkedIn Profile



Elliot  Ehrich's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Elliot  Ehrich


Elliot  Ehrich's known Social Networks And Potential Email Matches

Find all of Elliot  Ehrich's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Elliot Ehrich
Username Matches

                  ElliotEhrich
                  EhrichElliot
                  Elliot.Ehrich
                  Ehrich.Elliot
                  Elliot_Ehrich
                  Ehrich_Elliot
                  Elliot-Ehrich
                  Ehrich-Elliot
                  EEhrich
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
E Ehrich







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.














Elliot William Ehrich - Boston, MA | Intelius



























Sign In



We found Elliot William Ehrich in Boston, MA


Elliot William Ehrich

                                                                           Intelius found that Elliot William Ehrich  is  a male between 50 and 60 years old from Boston, MA.  We have connected them to
                19 addresses,
                10 phones,
                and 12 relatives or associates.
         






Get Report Now

Age

Elliot William Ehrich is in his 50s

Elliot Has Lived In

Boston, MA
Marblehead, MA
Chatham, NJ

Elliot's Relatives

Michael Ehrich
Fredric Ehrich
Nancy Donovan
Joan Ehrich







Elliot William Ehrich



Zodiac SignPisces



GenderMale



Professional Status
Senior Vice President-research And Dev at Alkermes



Get Report Now










Want to know more about Elliot? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Elliot, or use our people search engine to find others.
Get Background Check on Elliot William Ehrich
Get a Criminal Check on Elliot William Ehrich
Get a Public Record Report on Elliot William Ehrich
Get a People Search Report on Elliot William Ehrich


Elliot William Ehrich's Contact Information
Known Cities Lived In
Find out where Elliot William Ehrich has lived as well as Elliot William Ehrich's phone numbers and email addresses.




Elliot William Ehrich Has Lived in 5 States
Massachusetts Address for Elliot William Ehrich


150 B******** A** 

Boston, MA


Has Lived In

Boston, MA
Marblehead, MA


Get Full Address Report










Phone Numbers Associated with Elliot William Ehrich

(781) ***-**** - Lincoln, MA 
(617) ***-**** - Cambridge, MA 
(617) ***-**** - Cambridge, MA 


Get Full Phone Report



Email Addresses Associated with Elliot William Ehrich

e***********h@***.com
e*****h@***.com
e****h@***.com


Get Email Report




Elliot William Ehrich's Education Information
Known Schools Attended
Learn about Elliot William Ehrich's academic history.  Find out which schools Elliot William Ehrich attended, the dates attended as well as the degrees Elliot William Ehrich received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Elliot William Ehrich Has Attended 10 Schools
Stanford University 1986 – 1993               Elliot William Ehrich has a M.D. in Intermal Medicine Residency, Immunology and Rheumatology Fellowship               
Stanford University               1986 – 1993               Elliot William Ehrich has a Intermal Medicine Residency, Immunology and Rheumatology Fellowship in Immunology and Rheumatology Fellowship               
Columbia University College of Physicians and Surgeons               1982 – 1986               Elliot William Ehrich has a MD in Medicine               
Columbia University College of Physicians and Surgeons               1982 – 1986               Elliot William Ehrich has a Md, Medicine in Medicine               
Embl - European Molecular Biology Laboratory               1981 – 1983               Elliot William Ehrich has a  Mollecular Genetics               
Embl - European Molecular Biology Laboratory               1981 – 1983                              
Embl - European Molecular Biology Laboratory               1981 – 1983               Elliot William Ehrich has a  Mollecular Genetics               
Princeton University               1977 – 1981               Elliot William Ehrich has a BA in Biochemistry               
Princeton University               1977 – 1981               Elliot William Ehrich has a Ba, Biochemistry in Biochemistry               
Marblehead High School               1973 – 1977                              


Elliot William Ehrich's Professional Information
Information regarding Elliot William Ehrich's professional history.  Find out previous places Elliot William Ehrich has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Elliot William Ehrich Has Worked at 12 Places
Company: Alkermes
               Title: Senior Vice President-research And Dev
Company: Alkermes
               Title: Senior Vice President-research and Development, Chief Medical Officer
Elliot William Ehrich's Experience
Title: Senior Vice President-research And Dev
               Company: Alkermes
Job Details
               Company Size: $100 mil to less than $250 mil - Employee Range: 500 to less than 1,000
Title: Senior Vice President-research and Development, Chief Medical Officer
               Company: Alkermes
Job Details
               Company Size: $50 mil to less than $100 mil - Employee Range: 500 to less than 1,000
Additional Professional Information on Elliot William Ehrich

 See Elliot William Ehrich's LinkedIn Profile



Elliot William Ehrich's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Elliot William Ehrich


Elliot William Ehrich's known Social Networks And Potential Email Matches

Find all of Elliot William Ehrich's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Elliot Ehrich
Username Matches

                  ElliotEhrich
                  EhrichElliot
                  Elliot.Ehrich
                  Ehrich.Elliot
                  Elliot_Ehrich
                  Ehrich_Elliot
                  Elliot-Ehrich
                  Ehrich-Elliot
                  EEhrich
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
E Ehrich







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











﻿

Richard Pops, Chairman and CEO of Alkermes Biotech Company | Alkermes




























Home
Contact Us
Site Map














About Us

About Us


About Alkermes
Our Company
Message From the CEO
Locations


Leadership
Management Team
Board of Directors


Collaborations
Strategic Partners





Products

Products


Products
Products Overview


United States
ARISTADA®
VIVITROL®
U.S. Products Using Alkermes Technologies
Wholesaler and Purchasing Information


European Union
EU Products Using Alkermes Technologies





Research & Development

Research & Development


Research & Development
R&D Overview
Our R&D Approach
Pipeline
Technology Platforms
Manufacturing


Other Information
Clinical Trials
Expanded Access





Responsibility

Responsibility


Responsibility
Alkermes Corporate Giving
Investigator Initiated Trials
Educational Grants
Patient Engagement Support
ALKERMES Inspiration Grants™





Investors

Investors


Investors
Corporate Overview
Press Releases
Investor Events
Stock Information
SEC Filings
Annual Reports


Financials
Snapshot
Trading Statistics


Other Information
Email Alerts





News & Events

News & Events


News & Events
Press Releases
Media Kit





Careers

Careers


Careers
Working Together
Our Core Values
Total Rewards
Meet Our Employees
Recruiting Agencies
Equal Opportunity Employer


Job Opportunities
Jobs Overview
Field Sales Roles
All Available Roles












About Us







Home
About Us
Management Team












About Alkermes

Our Company
Message From the CEO
Locations

Leadership

Management Team
Board of Directors

Collaborations

Strategic Partners





Management Team










Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,900 employees. Alkermes has a diversified commercial product portfolio and a substantial clinical pipeline of central nervous system (CNS) product candidates. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Health Council.









Shane Cooke oversees corporate finance, commercial, business development, corporate planning, quality and manufacturing operations. Mr. Cooke joined Alkermes as President upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Previously, Mr. Cooke was Head of EDT and Executive Vice President of Elan from 2007 through the merger in 2011 and concurrently served as Chief Financial Officer of Elan Corporation from 2001 to May 2011. Mr. Cooke was appointed Director of Elan in May 2005. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company of which he was a founder. Mr. Cooke also previously held a number of senior positions in finance in the banking and aviation industries.  Mr. Cooke currently serves on the Board of Directors of Endo International plc and on the Board of Directors of Prothena Biosciences and Prothena Therapeutics, both subsidiaries of Prothena Corporation plc. Mr. Cooke is a chartered accountant and a graduate of University College Dublin, Ireland.









Kathy Biberstein oversees compliance, intellectual property, legal, policy, information technology, human resources and operations at the Waltham site. She also has responsibility for enterprise risk management. Ms. Biberstein held several senior legal positions prior to joining Alkermes in 2003, including General Counsel and member of the Executive Committee at Serono in Geneva, Switzerland from 1993 to 2000, where she built a worldwide legal department. Just prior to joining Alkermes, Ms. Biberstein was Of Counsel at Crowell & Moring LLC, and earlier in her career, Ms. Biberstein was a member of the Executive Board of the World Economic Forum. Ms. Biberstein received a Bachelor of Science degree from Kettering University and a Juris Doctor from the University of Michigan Law School.









Iain Brown is responsible for Alkermes’ accounting and financial reporting systems, as well as its tax, treasury, financial planning and analysis, and insurance functions. Mr. Brown has more than 20 years of experience in the biopharmaceutical industry. He joined Alkermes in 2003, prior to which he managed EMD Serono’s North America financial operations. Mr. Brown received a Bachelor of Science in Business Studies from the University of Bradford, England and is a Chartered Accountant.









Madeline Coffin leads Alkermes’ human resources team, with responsibility for global compensation and benefits, talent acquisition, employee engagement and growth and organization development. Ms. Coffin has held a number of senior human resource positions at companies including Analog Devices, Sun Microsystems, Wang Software and Bay Networks. Prior to joining Alkermes, she founded her own company, which focused on the strategic human resource needs of growing companies for clients in a broad range of industries. Ms. Coffin holds a Bachelor of Arts degree from Penn State University and a Master of Industrial and Labor Relations from Cornell University.









Elliot Ehrich leads the discovery, delivery science, research and development, project management and medical affairs functions at Alkermes. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., overseeing the successful clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. He also serves on the Scientific Advisory Boards of Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies, as well as a Strategic Advisor at Verge Genomics. Dr. Ehrich was a Phi Beta Kappa graduate of Princeton University where he received a Bachelor of Arts degree in biochemistry. He worked as a research associate at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and later earned his medical degree from Columbia University, College of Physicians and Surgeons. At Stanford University, Dr. Ehrich completed a residency in internal medicine and a clinical fellowship in the Department of Immunology and Rheumatology. He was subsequently a postdoctoral research fellow at the Howard Hughes Medical Institute at Stanford University School of Medicine, in the Department of Microbiology and Immunology.









Jim Frates serves as Chief Financial Officer of Alkermes. Prior to joining Alkermes in 1998, Mr. Frates was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Mr. Frates served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers.  Mr. Frates serves on the Board of Directors of SAGE Therapeutics and as a Trustee of the Roxbury Latin School. Mr. Frates received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.









David Gaffin serves as Alkermes’ in-house Chief Legal Officer, managing the operations of the legal department. Mr. Gaffin was most recently the U.S. General Counsel of Alkermes. Prior to joining the company in 2005, Mr. Gaffin held the role of Assistant General Counsel at Biogen Inc., where he provided legal counsel on product-related matters and negotiated collaboration and licensing transactions. Mr. Gaffin received a Bachelor of Arts degree from Harvard College, a Master of Business Administration from J.L. Kellogg Graduate School of Management and a Juris Doctor from Northwestern University School of Law.









Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs organization, Dr. Harris oversaw global development, registration and post-registration activities for multiple small-molecule and biologic medicines for obesity, bone, oncology, diabetes and women’s health indications. Dr. Harris received a Bachelor of Science degree from Boston College and a Ph.D. in biochemistry from the University of Wisconsin. She was subsequently a postdoctoral research fellow at the Massachusetts Institute of Technology, in the Department of Chemistry.









Craig Hopkinson, M.D., is responsible for evolving and executing the clinical development programs for the company’s pipeline of drug candidates. Dr. Hopkinson has more than 20 years of experience building and leading clinical development organizations and medical affairs groups in the biopharmaceutical industry. He has led multidisciplinary development teams in multiple therapeutic areas, including neuroscience, oncology, gastroenterology, infectious diseases, cardiovascular conditions, inflammation, genetic diseases, hematology and neurodegenerative diseases, and has extensive knowledge of clinical study design and the regulatory landscape. Most recently, Dr. Hopkinson held the position of Senior Vice President and Head of Global Medical Affairs for Vertex Pharmaceuticals. Prior to this role, Dr. Hopkinson held various executive management positions at Eisai Pharmaceuticals, including President of Eisai Value Maximization Systems, President and Chief Medical Officer of the Frontier Product Creation Unit, and Vice President of Medical Affairs, Oncology. In addition, Dr. Hopkinson served in leadership positions at Elan Pharmaceuticals, Actelion Pharmaceuticals and Pfizer. Dr. Hopkinson completed his Bachelor of Medicine and Bachelor of Surgery at the University of the Orange Free State in South Africa.









Blair Jackson leads business development at Alkermes, encompassing licensing efforts, new product evaluation and alliance management. Since joining Alkermes in 1999, Mr. Jackson has served in various roles within the company in both a scientific and corporate capacity. Mr. Jackson serves on the Board of Directors of Reset Therapeutics, Inc. Mr. Jackson received a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.









Mike Landine oversees Alkermes’ corporate development activities. Prior to leading corporate development, Mr. Landine served as Chief Financial Officer and Treasurer of Alkermes from March 1988 until June 1998. Mr. Landine is a member of the Board of Directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products. He also previously served on the Board of Directors of GTC Biotherapeutics, a biotechnology company, from 2005 to 2010. Mr. Landine received a Bachelor of Science degree in accounting from Bentley University and is a Certified Public Accountant.









Mark Namchuk leads research, pharmaceutical development, process development and nonclinical development of the company’s early-stage product pipeline at Alkermes. Prior to joining Alkermes in 2015, Dr. Namchuk served as Senior Vice President and Interim Global Head of Research for Vertex Pharmaceuticals, leading a group of more than 450 researchers in the discovery of transformational medicines in the areas of infectious disease, oncology, inflammatory diseases, neurology and cystic fibrosis. In addition, Dr. Namchuk developed the high throughput enzymology paradigm in support of the Vertex Chemogenomics effort and co-chaired the committee responsible for new-target selection and prosecution for the company. Earlier in his career, he served as the head of the biochemistry group at Cubist Pharmaceuticals. Dr. Namchuk obtained his doctorate in bioorganic chemistry from the University of British Columbia and completed a post-doctoral fellowship at the University of California, San Francisco.









Peter Norman leads the U.S. Government Affairs and Policy function for the company, which includes federal and state initiatives as well as programs with professional and patient organizations. Prior to joining Alkermes in 2013, Mr. Norman was the head of the Washington, D.C. office for Eisai, Inc. In addition, he’s held senior positions for Amylin Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novo Nordisk and the Biotechnology Industry Organization (BIO). Mr. Norman worked on public policy and regulatory strategies not only for Alzheimer’s disease, obesity and diabetes pharmaceutical products, but also healthcare reform and reimbursement issues. He received a Bachelor of Arts degree from Adrian College and a Juris Doctor from the University of Toledo College of Law.









Declan O’Connor is responsible for Alkermes’ manufacturing operations at the Athlone, Ireland and Wilmington, Ohio sites as well as its commercial and clinical supply chain functions. Mr. O’Connor is responsible for the strategic development of operations activities and site infrastructure development. He joined Alkermes as Vice President and General Manager in Athlone upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. In this role, he was responsible for the company’s FDA/EMA licensed multi-product development, manufacturing and packaging operations in Ireland. Mr. O’Connor held a number of senior operations positions for Elan including Vice President of Finance, Head of Global Supply Chain and Head of Finance U.S. Operations. Mr. O’Connor is a chartered accountant and a graduate of University College Dublin, Ireland.









Phil Shanahan is responsible for quality control, quality assurance and compliance at the Athlone, Ireland and Wilmington, Ohio sites, and the quality assurance function at the Waltham site. Dr. Shanahan joined Alkermes as Vice President, Quality Operations upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2011. Dr. Shanahan has more than 15 years of experience in quality operations. Prior to joining Elan, he served at Servier and Janssen Global Services, LLC. Dr. Shanahan obtained his doctorate in analytical biotechnology and his Bachelor of Science in chemistry from University College Cork. He holds a diploma in pharmaceutical manufacturing technology and is a certified Qualified Person (QP) for the release of product to the European Union.









Mark Stejbach serves as Chief Commercial Officer at Alkermes and is responsible for all aspects of Alkermes’ commercial functions, including sales, marketing, managed care and trade channels, commercial analytics, public policy and the development of commercial strategy for the company’s proprietary pipeline. Mr. Stejbach has more than 25 years of experience in biotech and pharmaceutical marketing, sales, managed care, and finance. Prior to joining Alkermes, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as Chief Commercial Officer. He previously held senior positions at Merck & Co. and Biogen Idec Inc. He currently serves on the Board of Directors of Flexion Therapeutics. Mr. Stejbach received his MBA from The Wharton School, University of Pennsylvania and a Bachelor of Science in mathematics from Virginia Tech.





Richard F. Pops



ShaneCooke



Kathryn L. Biberstein



IainBrown



Madeline D. Coffin



Elliot W. Ehrich, M.D.



James M. Frates



David J.Gaffin



Georgianna Harris, Ph.D.



Craig Hopkinson, M.D.



Blair C. Jackson



Michael J. Landine



Mark Namchuk, Ph.D.



PeterNorman



Declan O’Connor



Phil Shanahan, Ph.D.



Mark P. Stejbach










You are now leaving Alkermes.com.






About Us


Our Company


Message From the CEO


Locations


Management Team


Board of Directors


Strategic Partners


Products


Products Overview


ARISTADA®


VIVITROL®


U.S. Products Using Alkermes Technologies


EU Products Using Alkermes Technologies


Wholesaler and Purchasing Information




Research & Development


R&D Overview


Our R&D Approach


Pipeline


Technology Platforms


Manufacturing


Clinical Trials


Expanded Access


Responsibility


Alkermes Corporate Giving


Investigator Initiated Trials


Educational Grants


Patient Engagement Support


ALKERMES Inspiration Grants™




Investors


Corporate Overview


Press Releases


Investor Events


Stock Information


SEC Filings


Annual Reports


Snapshot


Trading Statistics


Email Alerts




News & Events


Press Releases


Media Kit


Careers


Working Together


Our Core Values


Total Rewards


Meet Our Employees


Recruiting Agencies


Equal Opportunity Employer


Jobs Overview


Field Sales Roles


All Available Roles








©2017 Alkermes. All Rights Reserved
Terms of Use
Privacy Policy















Elliot W. Ehrich M.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Elliot W. Ehrich M.D.
Executive Vice President, Research and Development and Chief Medical Officer at Alkermes


View Full Profile
Are you Elliot W. Ehrich M.D.? Claim your profile


 


Sign up for Equilar Atlas and view Elliot W. Ehrich M.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Elliot W. Ehrich M.D.'s  network and community.
												FOLLOW changes in Elliot W. Ehrich M.D.'s employment and money-in-motion.
												CONNECT with Elliot W. Ehrich M.D. through your network of contacts.
												








Elliot W. Ehrich M.D.'s Executive Work History


Current


Executive Vice President, Research and Development and Chief Medical Officer, 
Alkermes


Past
To view Elliot W. Ehrich M.D.'s complete executive work history, sign up now
Age
57

 
 


Elliot W. Ehrich M.D.'s Biography



Prior to assuming his current positions, from September 16, 2011 until February 2015, Dr. Ehrich was our Senior Vice President, Research and Development, and Chief Medical Officer. From May 2007 to September 16, 2011, Dr. Ehrich served as Senior Vice President, Research and Development, and Chief Medical Officer of Alkermes, Inc. Prior to this Dr. Ehrich served as Vice President, Science Development and Chief Medical Officer of Alkermes, Inc. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., Inc. ("Merck"), a publicly traded pharmaceutical company, overseeing the clinical development and registration of novel pha ...
(Read More)

			Prior to assuming his current positions, from September 16, 2011 until February 2015, Dr. Ehrich was our Senior Vice President, Research and Development, and Chief Medical Officer. From May 2007 to September 16, 2011, Dr. Ehrich served as Senior Vice President, Research and Development, and Chief Medical Officer of Alkermes, Inc. Prior to this Dr. Ehrich served as Vice President, Science Development and Chief Medical Officer of Alkermes, Inc. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., Inc. ("Merck"), a publicly traded pharmaceutical company, overseeing the clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. Dr. Ehrich worked as a research associate at the European Molecular Biology Laboratory in Heidelberg, Germany before attending medical school. Dr. Ehrich is also a member of the scientific advisory boards for Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies. Dr. Ehrich is also a strategic advisor to Verge Genomics.
		
Source: Alkermes on 04/13/2017
		
	

 






Sign up for Equilar Atlas and view Elliot W. Ehrich M.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Elliot W. Ehrich M.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Elliot W. Ehrich M.D.'s  network and community.
												FOLLOW changes in Elliot W. Ehrich M.D.'s employment and money-in-motion.
												CONNECT with Elliot W. Ehrich M.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Elliot W. Ehrich M.D.


















Elliot W. Ehrich M.D.'s Connections (46)





Sign up now to view Elliot W. Ehrich M.D.'s 46 connections »









Mark B. Skaletsky
Former Chairman of the Board, Catalyst Biosciences, Inc.









David W. Anstice
Former Executive Vice President, Strategy Initiatives, Merck & Co (Old)









Paul R. Schimmel
Board Member, aTyr Pharma









Wendy L. Dixon
Board Member, Incyte Corporation









Shane M. Cooke
President, Alkermes









Srdjan R. Stankovic
Executive Vice President and Head, Research and Development, ACADIA Pharmaceuticals Inc.









James M. Frates
Senior Vice President, Chief Financial Officer and Treasurer, Alkermes









David A. Broecker
Former President & Chief Executive Officer, Alkermes









Gordon G. Pugh
SVP, COO & CRO, Alkermes, Inc., Alkermes









Stuart Davidson
Former Board Member, Tonix Pharmaceuticals Holding Corp








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993


















Elliot W. Ehrich - Executive Vice President of Research & Development at Alkermes Plc



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





Elliot W. Ehrich
Executive Vice President of Research & Development at Alkermes Plc



Overview
In The News Relationships Paths
Education Memberships Career History Boards & Committees Public Holdings 


Elliot W. Ehrich
Executive Vice President of Research & Development at Alkermes Plc



 Overview



Age



56
                                  (Born 1961)
                                              




Board Seats



2





Number of Relationships



                This person is connected to 1,414 people.
              






 In The News
          See more




Business Wire
May 30, 2017





                        Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs                    





FierceBiotech
April 6, 2015





                        Alkermes heads to Phase III with a schizophrenia drug designed to spare the waistline                    





FierceBiotech
February 24, 2015





                        Alkermes dumps its pain drug after a Phase I disappointment                    





Boston Business Journal
February 24, 2015





                        Alkermes shares down after it stops development of pain pill                    





Business Wire
February 24, 2015





                        Alkermes Announces Results From Phase 1 Study of ALKS 7106                    







See full news coverage and complete stories with RelSci Professional.

Create Your News Feed








See  More 






 Relationships
              See Details




Richard Pops

Chief Executive Officer at Alkermes Plc




Iain M. Brown

Senior Vice President, Finance & Chief Accounting Officer at Alkermes Plc





Gordon G. Pugh

Former Senior Vice President, Chief Operating & Risk Officer at Alkermes Plc




Michael J. Landine

Director at Alkermes, Inc.





Malcolm Weir

Chairman & Chief Executive Officer at Heptares Therapeutics Ltd.




Michael R. Hanley

Former Chairman & Chief Executive Officer at Celtaxsys, Inc.





Pat Humphrey

Former Head of Research at Innoviva, Inc.




Richard Henderson

Member, Scientific Review Board at Howard Hughes Medical Institute, Inc.





Christopher G. Tate

Co-Founder at Heptares Therapeutics Ltd.




Stephen W. Fesik

Faculty Member at Vanderbilt University - Center For Structural Biology







See 1,404 more listings with RelSci Professional.

Start My Free Trial ➤








See 1,404 More 


 


 Paths to Elliot W. Ehrich



            Elliot W. Ehrich          




 You



 Connections via Relationship Science



 Elliot W. Ehrich






Sync your contacts to see how you can connect with Elliot W. Ehrich.

Start My Free Trial ➤








See  More 


 


 Educational Background



Doctorate Degree 


Columbia University

                  Columbia University is one of the world's most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields. The University recognizes the importance of its location in New York City and seeks to link its research and teaching to the vast resources of a great metropolis. It seeks to attract a diverse and international faculty and student body, to support research and teaching on global issues, and to create academic relationships with many countries and regions. It expects all areas of the university to advance knowledge and learning at the highest level and to convey the products of its efforts to the world.                




Bachelor of Arts Biochemistry 


Princeton University

                  Princeton University is a vibrant community of scholarship and learning that stands in the nation's service and in the service of all nations. Chartered in 1746, Princeton is the fourth-oldest college in the United States. Princeton is an independent, coeducational, nondenominational institution that provides undergraduate and graduate instruction in the humanities, social sciences, natural sciences and engineering.

As a world-renowned research university, Princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding. At the same time, Princeton is distinctive among research universities in its commitment to undergraduate teaching.

Today, more than 1,100 faculty members instruct approximately 5,000 undergraduate students and 2,500 graduate students. The University's generous financial aid program ensures that talented students from all economic backgrounds can afford a Princeton education.                




Medical Degree 


Columbia University - College of Physicians and Surgeons

                  Columbia University College of Physicians and Surgeons, often known as P&S, is a graduate school of Columbia University that is located in the Columbia University Medical Center in the Washington Heights neighborhood of Manhattan. Founded in 1767 by Samuel Bard as the medical department of King's College (now Columbia University), the College of Physicians and Surgeons was the first medical school in the thirteen colonies and hence, the United States, to award the Doctor of Medicine (M.D.) degree. Beginning in 1993, P&S also was the first U.S. medical school to hold a White Coat Ceremony.                





 Memberships



Fellow

                  Current                


American College of Rheumatology







 Career History



Executive Vice President of Research & Development

                                    2011 - Current                


Alkermes Plc


                  Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies, and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.                




Chief Medical Officer, Senior Vice President-Research & Development

                                    2000 - 2011                


Alkermes, Inc.


                  Alkermes, Inc. develops and manufactures pharmaceutical products. It offers Risperdal Consta, atypical antipsychotic medication approved for use in schizophrenia and Vivitrol, being developed as a once-monthly injection for the treatment of alcohol dependence. The company was founded by Michael Wall, Floyd Bloom, Frederick W. K. Brown, Paul Schimmel, and Alexander Rich on July 13, 1988 and is headquartered in Waltham, MA.                




Senior Director-Clinical Research

                                    Prior                


Merck & Co., Inc.


                  Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.                




Research Associate

                                    Prior                


The European Molecular Biology Laboratory






Fellow, Immunology & Rheumatology

                                    Prior                


Stanford University Medical Center


                  Stanford University Medical Center provided healthcare services. The firm offered patient care and the treatment in areas such as cardiac care, cancer treatment, neurosciences, surgery and organ transplants. The company was headquartered in Stanford, CA.                




Postdoctoral Research Fellow, Microbiology & Immunology

                                    Prior                


Howard Hughes Medical Institute, Inc.


                  The Howard Hughes Medical Institute (HHMI) is a nonprofit medical research organization that ranks as one of the nation’s largest philanthropies. HHMI plays a prominent role in advancing biomedical research and science education in the United States.

Founded in 1953 by aviator and industrialist Howard R. Hughes, HHMI is headquartered in Chevy Chase, Maryland, and employs more than 3,000 individuals across the U.S. HHMI has an endowment of $16.1 billion of which the Institute spent $800 million for research and distributed $119 million in grant support for science education in fiscal year 2012                





 Boards & Committees



Corporate Boards ▾




Member, Scientific Advisory Board

                    Current                  


Heptares Therapeutics Ltd.

                    Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.                  




Member, Scientific Advisory Board

                    Current                  


Aileron Therapeutics, Inc.

                    Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on developing and commercializing stapled peptides. Its proprietary Stapled Peptide drugs are used to attack the key drivers of complex diseases such as cancer, metabolic and endocrine conditions, and inflammation. Its products include ALRN-6924, MDMX, MDM2, and P53. Aileron Therapeutics was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.                  





 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Other Affiliations




              Elliot W. Ehrich is affiliated with
                            Alkermes Plc, Alkermes, Inc., Merck & Co., Inc., The European Molecular Biology Laboratory, Stanford University Medical Center, Howard Hughes Medical Institute, Inc., Heptares Therapeutics Ltd., Aileron Therapeutics, Inc..
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤
















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft









